Advanced Search

Project: COSMAHA Phase 2

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
COSMAHA Phase 2 Form Ian Saldanha 1

Associated Studies (each link opens a new tab)

Title Author Year
Clinic-based intervention reduces unprotected sexual behavior among HIV-infected patients in KwaZulu-Natal, South Africa: results of a pilot study. Cornman DH., Kiene SM., Christie S., Fisher WA., Shuper PA., Pillay S., Friedland GH., Thomas CM., Lodge L., Fisher JD. 2008
Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. Gilbert P., Ciccarone D., Gansky SA., Bangsberg DR., Clanon K., McPhee SJ., Calderón SH., Bogetz A., Gerbert B. 2008
Condom use promotion among isiXhosa speaking women living with HIV in the Western Cape Province, South Africa: a pilot study. Saleh-Onoya D., Reddy PS., Ruiter RA., Sifunda S., Wingood G., van den Borne B. 2009
Effects of a coping intervention on transmission risk behavior among people living with HIV/AIDS and a history of childhood sexual abuse. Sikkema KJ., Wilson PA., Hansen NB., Kochman A., Neufeld S., Ghebremichael MS., Kershaw T. 2008
A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program. Wingood GM., DiClemente RJ., Mikhail I., Lang DL., McCree DH., Davies SL., Hardin JW., Hook EW., Saag M. 2004
Controlled evaluation of a brief intervention for HIV prevention among injecting drug users not in treatment. Baker A., Kochan N., Dixon J., Heather N., Wodak A. 1994
Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. Avants SK., Margolin A., Usubiaga MH., Doebrick C. 2004
Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. Baker A., Heather N., Wodak A., Dixon J., Holt P. 1993
AIDS education in the jail setting Baxter S. 1991
Lowering HIV risk among ethnic minority drug users: comparing culturally targeted intervention to a standard intervention. Dushay RA., Singer M., Weeks MR., Rohena L., Gruber R. 2001
Preventing HIV/AIDS in drug-abusing incarcerated women through skills building and social support enhancement: preliminary outcomes. el-Bassel N., Ivanoff A., Schilling RF., Gilbert L., Borne D., Chen DR. 1995
Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing David R. Gibson, Jane Lovelle-Drache, Martin Young, Esther S. Hudes, and James L. Sorensen 1999
Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing David R. Gibson, Jane Lovelle-Drache, Martin Young, Esther S. Hudes, and James L. Sorensen 1999
An intervention for changing high-risk HIV behaviors of African American drug-dependent women. Harris RM., Bausell RB., Scott DE., Hetherington SE., Kavanagh KH. 1998
Evaluation of a cognitive-behavioural intervention for pregnant injecting drug users at risk of HIV infection. O'Neill K., Baker A., Cooke M., Collins E., Heather N., Wodak A. 1996
Effects of combined counseling and case management to reduce HIV risk behaviors among Hispanic drug injectors in Puerto Rico: a randomized controlled study. Robles RR., Reyes JC., Colón HM., Sahai H., Marrero CA., Matos TD., Calderón JM., Shepard EW. 2004
Building skills of recovering women drug users to reduce heterosexual AIDS transmission. Schilling RF., el-Bassel N., Schinke SP., Gordon K., Nichols S. -- Not Found --
A brief intervention for hazardous drinkers in a needle exchange program. Stein MD., Anderson B., Charuvastra A., Maksad J., Friedmann PD. 2002
HIV risk reduction among African-American women who inject drugs: a randomized controlled trial. Sterk CE., Theall KP., Elifson KW., Kidder D. 2003
Randomized controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users. Tucker T., Fry CL., Lintzeris N., Baldwin S., Ritter A., Donath S., Whelan G. 2004
Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Wechsberg WM., Lam WK., Zule WA., Bobashev G. 2004
Short-term impact evaluation of a social marketing campaign to prevent syphilis among men who have sex with men. Darrow WW., Biersteker S. 2008
HIV Prevention Among Sex Workers in India Ishika Basu, Smarajit Jana, Mary Jane Rotheram-Borus, Dallas Swendeman, Sung-Jae Lee, Peter Newman, and Robert Weiss 2004
No increase in HIV or sexually transmissible infection testing following a social marketing campaign among men who have sex with men. Guy R., Goller J., Leslie D., Thorpe R., Grierson J., Batrouney C., Kennedy M., Lewis J., Fairley C., Ginige S., Zablotska I., Hellard M. 2009
Can targeted HIV testing campaigns alter health-seeking behaviour? McOwan A., Gilleece Y., Chislett L., Mandalia S. 2002
Promoting HIV testing and condom use among Filipina commercial sex workers: findings from a quasi-experimental intervention study. Chiao C., Morisky DE., Ksobiech K., Malow RM. 2009
Results of a randomised trial of male condom promotion among Madagascar sex workers. Feldblum PJ., Hatzell T., Van Damme K., Nasution M., Rasamindrakotroka A., Grey TW. 2005
Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. Fontanet AL., Saba J., Chandelying V., Sakondhavat C., Bhiraleus P., Rugpao S., Chongsomchai C., Kiriwat O., Tovanabutra S., Dally L., Lange JM., Rojanapithayakorn W. 1998
Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. Ghys PD., Diallo MO., Ettiègne-Traoré V., Satten GA., Anoma CK., Maurice C., Kadjo JC., Coulibaly IM., Wiktor SZ., Greenberg AE., Laga M. 2001
Community-based prevention leads to an increase in condom use and a reduction in sexually transmitted infections (STIs) among men who have sex with men (MSM) and female sex workers (FSW): the Frontiers Prevention Project (FPP) evaluation results. Gutierrez JP., McPherson S., Fakoya A., Matheou A., Bertozzi SM. 2010
Randomised controlled trial of alternative male and female condom promotion strategies targeting sex workers in Madagascar. Hoke TH., Feldblum PJ., Damme KV., Nasution MD., Grey TW., Wong EL., Ralimamonjy L., Raharimalala L., Rasamindrakotroka A. 2007
Short-term effect of a cultural adaptation of voluntary counseling and testing among female sex workers in China: a quasi-experimental trial. Li X., Wang B., Fang X., Zhao R., Stanton B., Hong Y., Dong B., Liu W., Zhou Y., Liang S., Yang H. 2006
A randomized controlled trial of an HIV prevention intervention for street-based female sex workers in Yerevan, Armenia: preliminary evidence of efficacy. Markosyan K., Lang DL., Salazar LF., DiClemente RJ., Hardin JW., Darbinyan N., Joseph JB., Khurshudyan M. 2010
Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Patterson TL., Mausbach B., Lozada R., Staines-Orozco H., Semple SJ., Fraga-Vallejo M., Orozovich P., Abramovitz D., de la Torre A., Amaro H., Martinez G., Magis-Rodríguez C., Strathdee SA. 2008
Constraints faced by sex workers in use of female and male condoms for safer sex in urban zimbabwe. Ray S., van De Wijgert J., Mason P., Ndowa F., Maposhere C. 2001
Acceptability of a microenterprise intervention among female sex workers in Chennai, India. Sherman SG., Srikrishnan AK., Rivett KA., Liu SH., Solomon S., Celentano DD. 2010
Empowering sex workers in India to reduce vulnerability to HIV and sexually transmitted diseases. Swendeman D., Basu I., Das S., Jana S., Rotheram-Borus MJ. 2009
Substance use, sexual risk, and violence: HIV prevention intervention with sex workers in Pretoria. Wechsberg WM., Luseno WK., Lam WK., Parry CD., Morojele NK. 2006
Evaluation of a prevention intervention to reduce HIV Risk among Angolan soldiers. Bing EG., Cheng KG., Ortiz DJ., Ovalle-Bahamón RE., Ernesto F., Weiss RE., Boyer CB. 2008
Evaluation of a cognitive-behavioral, group, randomized controlled intervention trial to prevent sexually transmitted infections and unintended pregnancies in young women. Boyer CB., Shafer MA., Shaffer RA., Brodine SK., Pollack LM., Betsinger K., Chang YJ., Kraft HS., Schachter J. 2005
Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. Corbett EL., Dauya E., Matambo R., Cheung YB., Makamure B., Bassett MT., Chandiwana S., Munyati S., Mason PR., Butterworth AE., Godfrey-Faussett P., Hayes RJ. 2006
An information-motivation-behavioral skills (IMB) model-based HIV prevention intervention for truck drivers in India. Cornman DH., Schmiege SJ., Bryan A., Benziger TJ., Fisher JD. 2007
Effectiveness of a video-based motivational skills-building HIV risk-reduction intervention for female military personnel. Essien EJ., Mgbere O., Monjok E., Ekong E., Holstad MM., Kalichman SC. 2011
A randomized controlled trial to evaluate the relative efficacy of adding voluntary counseling and testing (VCT) to information dissemination in reducing HIV-related risk behaviors among Hong Kong male cross-border truck drivers. Lau JT., Tsui HY., Cheng S., Pang M. 2010
An Effective HIV Risk Reduction Protocol for Drug-Using Women Sex Workers Hilary L. Surratt and James A. Inciardi 2010
A sustainable behavioral intervention to increase condom use and reduce gonorrhea among sex workers in Singapore: 2-year follow-up. Wong ML., Chan KW., Koh D. -- Not Found --
Reductions in HIV risk among runaway youth. Rotheram-Borus MJ., Song J., Gwadz M., Lee M., Van Rossem R., Koopman C. 2003
Ecologically based family therapy outcome with substance abusing runaway adolescents. Slesnick N., Prestopnik JL. 2005
The impact of an integrated treatment on HIV risk behavior among homeless youth: a randomized controlled trial. Slesnick N., Kang MJ. 2008
A randomized social network HIV prevention trial with young men who have sex with men in Russia and Bulgaria. Amirkhanian YA., Kelly JA., Kabakchieva E., Kirsanova AV., Vassileva S., Takacs J., DiFranceisco WJ., McAuliffe TL., Khoursine RA., Mocsonaki L. 2005
A randomized controlled trial to test an HIV-prevention intervention for Latino gay and bisexual men: lessons learned. Carballo-Diéguez A., Dolezal C., Leu CS., Nieves L., Díaz F., Decena C., Balan I. 2005
Community-level HIV intervention in 5 cities: final outcome data from the CDC AIDS Community Demonstration Projects. -- Not Found -- 1999
Stress reduction training changed number of sexual partners but not immune function in men with HIV. Coates TJ., McKusick L., Kuno R., Stites DP. 1989
Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. Dilley JW., Woods WJ., Loeb L., Nelson K., Sheon N., Mullan J., Adler B., Chen S., McFarland W. 2007
Peer education has no significant impact on HIV risk behaviours among gay men in London. Elford J., Bolding G., Sherr L. 2001
Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Koblin B., Chesney M., Coates T. -- Not Found --
Does bar-based, peer-led sexual health promotion have a community-level effect amongst gay men in Scotland? Flowers P., Hart GJ., Williamson LM., Frankis JS., Der GJ. 2002
Outcomes and lessons from a pilot RCT of a community-based HIV prevention multi-session group intervention for gay men. Harding R., Bensley J., Corrigan N., Franks L., Stratman J., Waller Z., Warner J. 2004
Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. -- Not Found -- 2007
A cognitive behavioural intervention to reduce sexually transmitted infections among gay men: randomised trial. Imrie J., Stephenson JM., Cowan FM., Wanigaratne S., Billington AJ., Copas AJ., French L., French PD., Johnson AM. 2001
Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Kalichman SC., Rompa D., Cage M., DiFonzo K., Simpson D., Austin J., Luke W., Buckles J., Kyomugisha F., Benotsch E., Pinkerton S., Graham J. 2001
The Mpowerment Project: a community-level HIV prevention intervention for young gay men. Kegeles SM., Hays RB., Coates TJ. 1996
HIV risk behavior reduction following intervention with key opinion leaders of population: an experimental analysis. Kelly JA., St Lawrence JS., Diaz YE., Stevenson LY., Hauth AC., Brasfield TL., Kalichman SC., Smith JE., Andrew ME. 1991
Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Kelly JA., Murphy DA., Bahr GR., Kalichman SC., Morgan MG., Stevenson LY., Koob JJ., Brasfield TL., Bernstein BM. 1993
Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. Community HIV Prevention Research Collaborative. Kelly JA., Murphy DA., Sikkema KJ., McAuliffe TL., Roffman RA., Solomon LJ., Winett RA., Kalichman SC. 1997
HIV prevention with male prostitutes and patrons of hustler bars: replication of an HIV preventive intervention. Miller RL., Klotz D., Eckholdt HM. 1998
Reducing the sexual risk behaviors of HIV+ individuals: outcome of a randomized controlled trial. Patterson TL., Shaw WS., Semple SJ. 2003
A Telephone Based Brief Intervention Using Motivational Enhancement to Facilitate HIV Risk Reduction Among MSM: A Pilot Study Joseph F. Picciano,1,3 Roger A. Roffman,1 Seth C. Kalichman,2 Scott E. Rutledge,1 and James P. Berghuis1 2001
Prevention for substance-using HIV-positive young people: telephone and in-person delivery. Rotheram-Borus MJ., Swendeman D., Comulada WS., Weiss RE., Lee M., Lightfoot M. 2004
Socially Optimized Learning in a Virtual Environment: Reducing Risky Sexual Behavior Among Men Who Have Sex With Men Stephen J. Read1, Lynn C. Miller2, Paul Robert Appleby1, Mary E. Nwosu1, Sadina Reynaldo3, Ada Lauren1, & Anila Putcha1 2006
Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. Richardson JL., Milam J., McCutchan A., Stoyanoff S., Bolan R., Weiss J., Kemper C., Larsen RA., Hollander H., Weismuller P., Chou CP., Marks G. 2004
HIV-Prevention Group Counseling Delivered by Telephone: An Efficacy Trial with Gay and Bisexual Men Roger A. Roffman,1,3 Joseph F. Picciano,1 Rosemary Ryan,1 Blair Beadnell,1 Douglass Fisher,1 Lois Downey,1 and Seth C. Kalichman2 1997
Evaluation of the efficacy of AIDS education interventions for homosexually active men Brian Robert and Simon Rosser 1990
A randomized controlled intervention trial of a sexual health approach to long-term HIV risk reduction for men who have sex with men: effects of the intervention on unsafe sexual behavior. Rosser BR., Bockting WO., Rugg DL., Robinson BB., Ross MW., Bauer GR., Coleman E. 2002
Efficacy of a preventive intervention for youths living with HIV. Rotheram-Borus MJ., Lee MB., Murphy DA., Futterman D., Duan N., Birnbaum JM., Lightfoot M. 2001
Reducing AIDS Risk Among Men Who Have Sex with Men in Salvador, Brazil Marcia Sampaio,1 Carlos Brites,2 Ron Stall,3 Esther S. Hudes,3 and Norman Hearst3,4 2002
Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Shoptaw S., Reback CJ., Peck JA., Yang X., Rotheram-Fuller E., Larkins S., Veniegas RC., Freese TE., Hucks-Ortiz C. 2005
Case management for substance abusers with HIV/AIDS: a randomized clinical trial. Sorensen JL., Dilley J., London J., Okin RL., Delucchi KL., Phibbs CS. 2003
Effects of a peer-led behavioral intervention to reduce HIV transmission and promote serostatus disclosure among HIV-seropositive gay and bisexual men. Wolitski RJ., Gómez CA., Parsons JT. 2005
A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. Collier AC., Ribaudo H., Mukherjee AL., Feinberg J., Fischl MA., Chesney M. 2005
A randomized clinical trial of two telephone-delivered, mental health interventions for HIV-infected persons in rural areas of the United States. Heckman TG., Carlson B. 2007
Brief behavioral self-regulation counseling for HIV treatment adherence delivered by cell phone: an initial test of concept trial. Kalichman SC., Kalichman MO., Cherry C., Swetzes C., Amaral CM., White D., Jones M., Grebler T., Eaton L. 2011
Telephone-administered motivational interviewing reduces risky sexual behavior in HIV-positive late middle-age and older adults: a pilot randomized controlled trial. Lovejoy TI., Heckman TG., Suhr JA., Anderson T., Heckman BD., France CR. 2011
Telephone-delivered, interpersonal psychotherapy for HIV-infected rural persons with depression: a pilot trial. Ransom D., Heckman TG., Anderson T., Garske J., Holroyd K., Basta T. 2008
Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. Reynolds NR., Testa MA., Su M., Chesney MA., Neidig JL., Frank I., Smith S., Ickovics J., Robbins GK. 2008
A telephone-based intervention for depression in HIV patients: negative results from a randomized clinical trial. Stein MD., Herman DS., Bishop D., Anderson BJ., Trisvan E., Lopez R., Flanigan T., Miller I. 2007
Telephone-Administered Intervention to Improve Medication Adherence in HIV-Infected Rural Persons: A Pilot Randomized Clinical Trial Rewadee Watakakosol
Impact of telephonic psycho-social support on adherence to post-exposure prophylaxis (PEP) after rape. Abrahams N., Jewkes R., Lombard C., Mathews S., Campbell J., Meel B. 2010
Telephone vs. face-to-face notification of HIV results in high-risk youth. Tsu RC., Burm ML., Gilhooly JA., Sells CW. 2002
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial. Becker S., Mlay R., Schwandt HM., Lyamuya E. 2010
Sexual behavior of HIV discordant couples after HIV counseling and testing. Allen S., Meinzen-Derr J., Kautzman M., Zulu I., Trask S., Fideli U., Musonda R., Kasolo F., Gao F., Haworth A. 2003
Behaviour change in clients of health centre-based voluntary HIV counselling and testing services in Kenya. Arthur G., Nduba V., Forsythe S., Mutemi R., Odhiambo J., Gilks C. 2007
Rapid voluntary testing and counseling for HIV. Acceptability and feasibility in Zambian antenatal care clinics. Bakari JP., McKenna S., Myrick A., Mwinga K., Bhat GJ., Allen S. 2000
HIV voluntary counseling and testing among injection drug users in south China: a study of a non-government organization based program. Chen HT., Liang S., Liao Q., Wang S., Schumacher JE., Creger TN., Wilson CM., Dong B., Vermund SH. 2007
HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. Corbett EL., Makamure B., Cheung YB., Dauya E., Matambo R., Bandason T., Munyati SS., Mason PR., Butterworth AE., Hayes RJ. 2007
Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. Cremin I., Nyamukapa C., Sherr L., Hallett TB., Chawira G., Cauchemez S., Lopman B., Garnett GP., Gregson S. 2010
Positive and negative life events after counselling and testing: the Voluntary HIV-1 Counselling and Testing Efficacy Study. Grinstead OA., Gregorich SE., Choi KH., Coates T. 2001
HIV incidence and risk behaviours after voluntary HIV counselling and testing (VCT) among adults aged 19-35 years living in peri-urban communities around Chiang Mai city in northern Thailand, 1999. Kawichai S., Beyrer C., Khamboonruang C., Celentano DD., Natpratan C., Rungruengthanakit K., Nelson KE. 2004
Voluntary counseling and testing by nurse counselors: what is the role of routine repeated testing after a negative result? Matambo R., Dauya E., Mutswanga J., Makanza E., Chandiwana S., Mason PR., Butterworth AE., Corbett EL. 2006
Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. Matovu JK., Gray RH., Makumbi F., Wawer MJ., Serwadda D., Kigozi G., Sewankambo NK., Nalugoda F. 2005
Condom use after voluntary counselling and testing in central Mozambique. Mola OD., Mercer MA., Asghar RJ., Gimbel-Sherr KH., Gimbel-Sherr S., Micek MA., Gloyd SS. 2006
Sexual risk behaviour reduction associated with voluntary HIV counselling and testing in HIV infected patients in Thailand. Müller O., Sarangbin S., Ruxrungtham K., Sittitrai W., Phanuphak P. 1995
Sexual practices of HIV discordant and concordant couples in Rwanda: effects of a testing and counselling programme for men. Roth DL., Stewart KE., Clay OJ., van Der Straten A., Karita E., Allen S. 2001
Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. -- Not Found -- 2000
Acceptability of HIV/AIDS counseling and testing among premarital couples in China. Wu Z., Rou K., Xu C., Lou W., Detels R. 2005
A randomized trial on acceptability of voluntary HIV counselling and testing. Fylkesnes K., Siziya S. 2004
Is a general women's health promotion program as effective as an HIV-intensive prevention program in reducing HIV risk among Hispanic women? Raj A., Amaro H., Cranston K., Martin B., Cabral H., Navarro A., Conron K. -- Not Found --
HIV testing: changing trends at a clinic for sexually transmitted diseases in London. Beck EJ., Cunningham DG., Moss VW., Harris JR., Pinching AJ., Jeffries DJ. 1987
An Update on HIV-testing at a London Sexually Transmitted Diseases Clinic: long-term impact of the AIDS media campaigns Eduard J Beck, Catrina Donegan, Colin Kenny, Colin S Cohen, Vincent Moss, Patrick Terry, Gill S Underhill, Donald J Jeffries, Anthony J Pinching, David L Miller, J R William Harris, Deirdre G Cunningham 1990
Uptake and acceptability of antenatal HIV testing: randomised controlled trial of different methods of offering the test. Simpson WM., Johnstone FD., Boyd FM., Goldberg DJ., Hart GJ., Prescott RJ. 1998
A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability and Annex: Antenatal HIV testing - assessment of a routine voluntary approach. Simpson WM., Johnstone FD., Boyd FM., Goldberg DJ., Hart GJ., Gormley SM., Hamilton BA. 1999
Evaluating the outcomes of parent-child family life education. Anderson NL., Koniak-Griffin D., Keenan CK., Uman G., Duggal BR., Casey C. 1999
Effects of a parent-child communications intervention on young adolescents' risk for early onset of sexual intercourse. Blake SM., Simkin L., Ledsky R., Perkins C., Calabrese JM. -- Not Found --
Adult identity mentoring: reducing sexual risk for African-American seventh grade students. Clark LF., Miller KS., Nagy SS., Avery J., Roth DL., Liddon N., Mukherjee S. 2005
Abstinence, protection, and decision-making: experimental trials on prototypic AIDS programs Jeanne T.Hernandez and Frank J.Smith1 1990
The impact of the Postponing Sexual Involvement curriculum among youths in California. Kirby D., Korpi M., Barth RP., Cagampang HH. -- Not Found --
Impact Evaluation of Facts & Feelings: A Home-Based Video Sex Education Curriculum Brent C. Miller, Maria C. Norton, Glen O. Jenson, Thomas R. Lee, CynthiaChristopherson and Pamela K. King 1993
Impacts of Four Title V, Section 510 Abstinence Education Programs Christopher Trenholm Barbara Devaney Ken Fortson Lisa Quay Justin Wheeler Melissa Clark 2007
Postponing sexual intercourse among urban junior high school students-a randomized controlled evaluation. Aarons SJ., Jenkins RR., Raine TR., El-Khorazaty MN., Woodward KM., Williams RL., Clark MC., Wingrove BK. 2000
A STD/HIV prevention trial among adolescents in managed care. Boekeloo BO., Schamus LA., Simmens SJ., Cheng TL., O'Connor K., D'Angelo LJ. 1999
Safer choices: reducing teen pregnancy, HIV, and STDs. Coyle K., Basen-Engquist K., Kirby D., Parcel G., Banspach S., Collins J., Baumler E., Carvajal S., Harrist R. 2001
Draw the line/respect the line: a randomized trial of a middle school intervention to reduce sexual risk behaviors. Coyle KK., Kirby DB., Marín BV., Gómez CA., Gregorich SE. 2004
All4You! A randomized trial of an HIV, other STDs, and pregnancy prevention intervention for alternative school students. Coyle KK., Kirby DB., Robin LE., Banspach SW., Baumler E., Glassman JR. 2006
Mothers' effectiveness as HIV risk reduction educators for adolescent daughters. Dancy BL., Crittenden KS., Talashek ML. 2006
Reproductive health counseling for young men: what does it do? Danielson R., Marcy S., Plunkett A., Wiest W., Greenlick MR. -- Not Found --
Keepin' it R.E.A.L.!: results of a mother-adolescent HIV prevention program. DiIorio C., Resnicow K., McCarty F., De AK., Dudley WN., Wang DT., Denzmore P. -- Not Found --
REAL men: a group-randomized trial of an HIV prevention intervention for adolescent boys. DiIorio C., McCarty F., Resnicow K., Lehr S., Denzmore P. 2007
Peer counseling in a culturally specific adolescent pregnancy prevention program. Ferguson SL. 1998
Reductions in HIV risk-associated sexual behaviors among black male adolescents: effects of an AIDS prevention intervention. Jemmott JB., Jemmott LS., Fong GT. 1992
Abstinence and safer sex HIV risk-reduction interventions for African American adolescents: a randomized controlled trial. Jemmott JB., Jemmott LS., Fong GT. 1998
Reducing HIV risk-associated sexual behavior among African American adolescents: testing the generality of intervention effects. Jemmott JB., Jemmott LS., Fong GT., McCaffree K. 1999
The effect of tailoring a model HIV prevention program for local adolescent target audiences. Kennedy MG., Mizuno Y., Hoffman R., Baume C., Strand J. 2000
Using randomized designs to evaluate client-centered programs to prevent adolescent pregnancy. McBride D., Gienapp A. -- Not Found --
Long-term reductions in sexual initiation and sexual activity among urban middle schoolers in the reach for health service learning program. O'Donnell L., Stueve A., O'Donnell C., Duran R., San Doval A., Wilson RF., Haber D., Perry E., Pleck JH. 2002
Outcomes of a randomized, controlled community-level HIV prevention intervention for adolescents in low-income housing developments. Sikkema KJ., Anderson ES., Kelly JA., Winett RA., Gore-Felton C., Roffman RA., Heckman TG., Graves K., Hoffmann RG., Brondino MJ. 2005
A randomized, controlled effectiveness trial of an AIDS prevention program for low-income African-American youths. Stanton BF., Li X., Ricardo I., Galbraith J., Feigelman S., Kaljee L. 1996
Parental underestimates of adolescent risk behavior: a randomized, controlled trial of a parental monitoring intervention. Stanton BF., Li X., Galbraith J., Cornick G., Feigelman S., Kaljee L., Zhou Y. 2000
Trial of an urban adolescent sexual risk-reduction intervention for rural youth: a promising but imperfect fit. Stanton B., Harris C., Cottrell L., Li X., Gibson C., Guo J., Pack R., Galbraith J., Pendleton S., Wu Y., Burns J., Cole M., Marshall S. 2006
A randomized controlled trial testing an HIV prevention intervention for Latino youth. Villarruel AM., Jemmott JB., Jemmott LS. 2006
Sustaining and broadening intervention impact: a longitudinal randomized trial of 3 adolescent risk reduction approaches. Wu Y., Stanton BF., Galbraith J., Kaljee L., Cottrell L., Li X., Harris CV., D'Alessandri D., Burns JM. 2003
Effects of a HIV risk reduction education program among injection drug users in Puerto Rico. Colón HM., Robles RR., Freeman D., Matos T. 1993
A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Margolin A., Avants SK., Warburton LA., Hawkins KA., Shi J. 2003
A Sexual Risk Reduction Intervention for Female Sex Workers in Mexico: Design and Baseline Characteristics Thomas L. Patterson, PhD Shirley J. Semple, PhD Miguel Fraga, MD, MS Jesus Bucardo, MD, MPH Adela De la Torre, PhD Juan Salazar-Reyna, MD Prisci Orozovich, MPH Hugo Salvador Staines Orozco, MD Hortensia Amaro, PhD Carlos Magis-Rodríguez, MD, MPH Steffanie A. Strathdee, PhD 2006
The efficacy of brief group counseling in HIV risk reduction among homosexual Asian and Pacific Islander men. Choi KH., Lew S., Vittinghoff E., Catania JA., Barrett DC., Coates TJ. 1996
A randomized trial of an education and support program for HIV-infected individuals. Cleary PD., Van Devanter N., Steilen M., Stuart A., Shipton-Levy R., McMullen W., Rogers TF., Singer E., Avorn J., Pindyck J. 1995
Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. Dilley JW., Woods WJ., Sabatino J., Lihatsh T., Adler B., Casey S., Rinaldi J., Brand R., McFarland W. 2002
Behavioral intervention to reduce AIDS risk activities. Kelly JA., St Lawrence JS., Hood HV., Brasfield TL. 1989
Evaluation of an HIV risk reduction intervention among African-American homosexual and bisexual men. Peterson JL., Coates TJ., Catania J., Hauck WW., Acree M., Daigle D., Hillard B., Middleton L., Hearst N. 1996
Peer-led sexual health promotion with young gay and bisexual men – results of The HAPEER Project Jonathan Shepherd Katherine Weare and Glenn Turner 1997
An outcome evaluation to measure changes in sexual risk-taking among gay men undergoing substance use disorder treatment. Stall RD., Paul JP., Barrett DC., Crosby GM., Bein E. 1999
The talking sex project: Results of a randomized controlled trial of small-group AIDS education for 612 gay and bisexual men F. Tudiver, T.Myers, RG. Kurtz, K. ORR, C. Rowe, E. Jackson, S. Bullock 1992
AIDS prevention in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction interventions. Valdiserri RO., Lyter DW., Leviton LC., Callahan CM., Kingsley LA., Rinaldo CR. 1989
Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe. Machekano R., McFarland W., Mbizvo MT., Bassett MT., Katzenstein D., Latif AS. 1998
Does HIV VCT reduce risk behaviors? An observational study in Guatemala City. Samayoa B., Anderson MR., O'Sullivan LF., Patricia K., Pacheco A., Matos A., Reyes DA., Setru S., Arathoon E. 2010
Evaluation of the Quebec Public Information Campaign and Human Immunodeficiency Virus (HIV) Antibody Screening Program directed to persons transfused between 1978 and 1985. Poulin C., Alary M., Massé R. -- Not Found --
Evaluation of an AbstinenceBased Curriculum for Early Adolescents:First Year Changes in Sex Attitudes, Knowledge and Behavior Goldfarb, Eva S; Donnelly, Joseph; Duncan, David F; Young, Michael; Eadie, Carolyn; et al. 1999
Teen Incentives Program: evaluation of a health promotion model for adolescent pregnancy prevention. Smith MA. -- Not Found --
Cognitive-behavioral intervention to reduce African American adolescents' risk for HIV infection. St Lawrence JS., Brasfield TL., Jefferson KW., Alleyne E., O'Bannon RE., Shirley A. 1995
Comparison of education versus behavioral skills training interventions in lowering sexual HIV-risk behavior of substance-dependent adolescents. St Lawrence JS., Jefferson KW., Alleyne E., Brasfield TL. 1995
Sexual risk reduction and anger management interventions for incarcerated male adolescents: A randomized controlled trial of two interventions JS St. Lawrence, RA Crosby, L Belcher, N Yazdani, TL Brasfield 1999
Reducing STD and HIV risk behavior of substance-dependent adolescents: a randomized controlled trial. St Lawrence JS., Crosby RA., Brasfield TL., O'Bannon RE. 2002
Impact of peer education on HIV infection in Zimbabwe. Bassett M. 1998
Looking for men in all the wrong places...: HIV prevention small-group programs do not reach high risk gay men. Hoff CC., Kegeles SM., Acree M., Stall R., Paul J., Ekstrand M., Coates TJ. 1997
Evaluation of a safe-sex intervention programme among sex workers in Singapore. Archibald CP., Chan RK., Wong ML., Goh A., Goh CL. -- Not Found --
Preventing unprotected anal intercourse in gay men: a comparison of two intervention techniques. Gold RS., Rosenthal DA. -- Not Found --
Examining self-justifications for unsafe sex as a technique of AIDS education: the importance of personal relevance. Gold RS., Rosenthal DA. 1998
HIV testing in Glasgow Genito-Urinary Medicine Clinics 1985-1987. Joshi UY., Cameron SO., Sommerville JM., Sommerville RG. 1988
The effect of "Magic" Johnson's HIV disclosure on anonymous HIV counseling and testing services in New York State JM Tesoriero and MD Sorin 1992
Changes in HIV risk behaviors among counseled injecting drug users Mandell W.
Using message framing to motivate HIV testing among low-income, ethnic minority women Apanovitch A.M.
Prevention of HIV-1 infection with early antiretroviral therapy. Cohen MS., Chen YQ., McCauley M., Gamble T., Hosseinipour MC., Kumarasamy N., Hakim JG., Kumwenda J., Grinsztejn B., Pilotto JH., Godbole SV., Mehendale S., Chariyalertsak S., Santos BR., Mayer KH., Hoffman IF., Eshleman SH., Piwowar-Manning E., Wang L., Makhema J., Mills LA., de Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha TE., Nielsen-Saines K., Celentano D., Essex M., Fleming TR. 2011
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. Auvert B., Taljaard D., Lagarde E., Sobngwi-Tambekou J., Sitta R., Puren A. 2005
Adult male circumcision: effects on sexual function and sexual satisfaction in Kisumu, Kenya. Krieger JN., Mehta SD., Bailey RC., Agot K., Ndinya-Achola JO., Parker C., Moses S. 2008
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Gray RH., Kigozi G., Serwadda D., Makumbi F., Watya S., Nalugoda F., Kiwanuka N., Moulton LH., Chaudhary MA., Chen MZ., Sewankambo NK., Wabwire-Mangen F., Bacon MC., Williams CF., Opendi P., Reynolds SJ., Laeyendecker O., Quinn TC., Wawer MJ. 2007
Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Kreiss J., Ngugi E., Holmes K., Ndinya-Achola J., Waiyaki P., Roberts PL., Ruminjo I., Sajabi R., Kimata J., Fleming TR. -- Not Found --
Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Richardson BA., Lavreys L., Martin HL., Stevens CE., Ngugi E., Mandaliya K., Bwayo J., Ndinya-Achola J., Kreiss JK. 2001
A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. Roddy RE., Zekeng L., Ryan KA., Tamoufé U., Weir SS., Wong EL. 1998
Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. Roddy RE., Zekeng L., Ryan KA., Tamoufé U., Tweedy KG. 2002
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Mukenge-Tshibaka L., Ettiègne-Traoré V., Uaheowitchai C., Karim SS., Mâsse B., Perriëns J., Laga M. 2002
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. Baeten JM., Donnell D., Ndase P., Mugo NR., Campbell JD., Wangisi J., Tappero JW., Bukusi EA., Cohen CR., Katabira E., Ronald A., Tumwesigye E., Were E., Fife KH., Kiarie J., Farquhar C., John-Stewart G., Kakia A., Odoyo J., Mucunguzi A., Nakku-Joloba E., Twesigye R., Ngure K., Apaka C., Tamooh H., Gabona F., Mujugira A., Panteleeff D., Thomas KK., Kidoguchi L., Krows M., Revall J., Morrison S., Haugen H., Emmanuel-Ogier M., Ondrejcek L., Coombs RW., Frenkel L., Hendrix C., Bumpus NN., Bangsberg D., Haberer JE., Stevens WS., Lingappa JR., Celum C. 2012
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. Grant RM., Lama JR., Anderson PL., McMahan V., Liu AY., Vargas L., Goicochea P., Casapía M., Guanira-Carranza JV., Ramirez-Cardich ME., Montoya-Herrera O., Fernández T., Veloso VG., Buchbinder SP., Chariyalertsak S., Schechter M., Bekker LG., Mayer KH., Kallás EG., Amico KR., Mulligan K., Bushman LR., Hance RJ., Ganoza C., Defechereux P., Postle B., Wang F., McConnell JJ., Zheng JH., Lee J., Rooney JF., Jaffe HS., Martinez AI., Burns DN., Glidden DV. 2010
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. Peterson L., Taylor D., Roddy R., Belai G., Phillips P., Nanda K., Grant R., Clarke EE., Doh AS., Ridzon R., Jaffe HS., Cates W. 2007
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. Thigpen MC., Kebaabetswe PM., Paxton LA., Smith DK., Rose CE., Segolodi TM., Henderson FL., Pathak SR., Soud FA., Chillag KL., Mutanhaurwa R., Chirwa LI., Kasonde M., Abebe D., Buliva E., Gvetadze RJ., Johnson S., Sukalac T., Thomas VT., Hart C., Johnson JA., Malotte CK., Hendrix CW., Brooks JT. 2012
Preexposure prophylaxis for HIV infection among African women. Van Damme L., Corneli A., Ahmed K., Agot K., Lombaard J., Kapiga S., Malahleha M., Owino F., Manongi R., Onyango J., Temu L., Monedi MC., Mak'Oketch P., Makanda M., Reblin I., Makatu SE., Saylor L., Kiernan H., Kirkendale S., Wong C., Grant R., Kashuba A., Nanda K., Mandala J., Fransen K., Deese J., Crucitti T., Mastro TD., Taylor D. 2012
Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, Kenya. Gaillard P., Mwanyumba F., Verhofstede C., Claeys P., Chohan V., Goetghebeur E., Mandaliya K., Ndinya-Achola J., Temmerman M. 2001
15 Month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Mandelbrot L., Msellati P., Meda N., Leroy V., Likikouët R., Van de Perre P., Dequae-Merchadoux L., Sylla-Koko F., Ouangre A., Ouassa T., Ramon R., Gautier-Charpentier L., Cartoux M., Dosso M., Dabis F., Welffens-Ekra C. 2002
Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission. Bhoopat L., Khunamornpong S., Lerdsrimongkol P., Sirivatanapa P., Sethavanich S., Limtrakul A., Gomutbuthra V., Kajanavanich S., Thorner PS., Bhoopat T. 2005
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. Chi BH., Chintu N., Cantrell RA., Kankasa C., Kruse G., Mbewe F., Sinkala M., Smith PJ., Stringer EM., Stringer JS. 2008
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. Chung MH., Kiarie JN., Richardson BA., Lehman DA., Overbaugh J., John-Stewart GC. 2005
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. Chung MH., Kiarie JN., Richardson BA., Lehman DA., Overbaugh J., Kinuthia J., Njiri F., John-Stewart GC. 2008
6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Dabis F., Msellati P., Meda N., Welffens-Ekra C., You B., Manigart O., Leroy V., Simonon A., Cartoux M., Combe P., Ouangré A., Ramon R., Ky-Zerbo O., Montcho C., Salamon R., Rouzioux C., Van de Perre P., Mandelbrot L. 1999
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. Gray GE., Urban M., Chersich MF., Bolton C., van Niekerk R., Violari A., Stevens W., McIntyre JA. 2005
Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. Gray G., Violari A., McIntyre J., Jivkov B., Schnittman S., Reynolds L., Ledeine JM. 2006
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Guay LA., Musoke P., Fleming T., Bagenda D., Allen M., Nakabiito C., Sherman J., Bakaki P., Ducar C., Deseyve M., Emel L., Mirochnick M., Fowler MG., Mofenson L., Miotti P., Dransfield K., Bray D., Mmiro F., Jackson JB. 1999
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. de Vincenzi I. 2011
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. Kiarie JN., Kreiss JK., Richardson BA., John-Stewart GC. 2003
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Shapiro RL., Thior I., Gilbert PB., Lockman S., Wester C., Smeaton LM., Stevens L., Heymann SJ., Ndung'u T., Gaseitsiwe S., Novitsky V., Makhema J., Lagakos S., Essex M. 2006
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. Shapiro RL., Hughes MD., Ogwu A., Kitch D., Lockman S., Moffat C., Makhema J., Moyo S., Thior I., McIntosh K., van Widenfelt E., Leidner J., Powis K., Asmelash A., Tumbare E., Zwerski S., Sharma U., Handelsman E., Mburu K., Jayeoba O., Moko E., Souda S., Lubega E., Akhtar M., Wester C., Tuomola R., Snowden W., Martinez-Tristani M., Mazhani L., Essex M. 2010
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Connor EM., Sperling RS., Gelber R., Kiselev P., Scott G., O'Sullivan MJ., VanDyke R., Bey M., Shearer W., Jacobson RL. 1994
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. Dorenbaum A., Cunningham CK., Gelber RD., Culnane M., Mofenson L., Britto P., Rekacewicz C., Newell ML., Delfraissy JF., Cunningham-Schrader B., Mirochnick M., Sullivan JL. 2002
Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. -- Not Found -- 2002
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. Lallemant M., Jourdain G., Le Coeur S., Kim S., Koetsawang S., Comeau AM., Phoolcharoen W., Essex M., McIntosh K., Vithayasai V. 2000
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. Lallemant M., Jourdain G., Le Coeur S., Mary JY., Ngo-Giang-Huong N., Koetsawang S., Kanshana S., McIntosh K., Thaineua V. 2004
Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Wiktor SZ., Ekpini E., Karon JM., Nkengasong J., Maurice C., Severin ST., Roels TH., Kouassi MK., Lackritz EM., Coulibaly IM., Greenberg AE. 1999
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Taha TE., Kumwenda NI., Gibbons A., Broadhead RL., Fiscus S., Lema V., Liomba G., Nkhoma C., Miotti PG., Hoover DR. 2003
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. Taha TE., Kumwenda NI., Hoover DR., Fiscus SA., Kafulafula G., Nkhoma C., Nour S., Chen S., Liomba G., Miotti PG., Broadhead RL. 2004
Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Shaffer N., Chuachoowong R., Mock PA., Bhadrakom C., Siriwasin W., Young NL., Chotpitayasunondh T., Chearskul S., Roongpisuthipong A., Chinayon P., Karon J., Mastro TD., Simonds RJ. 1999
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Thistle P., Spitzer RF., Glazier RH., Pilon R., Arbess G., Simor A., Boyle E., Chitsike I., Chipato T., Gottesman M., Silverman M. 2007
Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. -- Not Found -- 1999
Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group. Coutsoudis A., Pillay K., Spooner E., Kuhn L., Coovadia HM. 1999
Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. Fawzi WW., Msamanga GI., Hunter D., Renjifo B., Antelman G., Bang H., Manji K., Kapiga S., Mwakagile D., Essex M., Spiegelman D. 2002
Effect of multimicronutrient supplementation on gestational length and birth size: a randomized, placebo-controlled, double-blind effectiveness trial in Zimbabwe. Friis H., Gomo E., Nyazema N., Ndhlovu P., Krarup H., Kaestel P., Michaelsen KF. 2004
Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. Humphrey JH., Iliff PJ., Marinda ET., Mutasa K., Moulton LH., Chidawanyika H., Ward BJ., Nathoo KJ., Malaba LC., Zijenah LS., Zvandasara P., Ntozini R., Mzengeza F., Mahomva AI., Ruff AJ., Mbizvo MT., Zunguza CD. 2006
Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. Kumwenda N., Miotti PG., Taha TE., Broadhead R., Biggar RJ., Jackson JB., Melikian G., Semba RD. 2002
Effects of early, abrupt weaning on HIV-free survival of children in Zambia. Kuhn L., Aldrovandi GM., Sinkala M., Kankasa C., Semrau K., Mwiya M., Kasonde P., Scott N., Vwalika C., Walter J., Bulterys M., Tsai WY., Thea DM. 2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. Kumwenda NI., Hoover DR., Mofenson LM., Thigpen MC., Kafulafula G., Li Q., Mipando L., Nkanaunena K., Mebrahtu T., Bulterys M., Fowler MG., Taha TE. 2008
Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. Nduati R., John G., Mbori-Ngacha D., Richardson B., Overbaugh J., Mwatha A., Ndinya-Achola J., Bwayo J., Onyango FE., Hughes J., Kreiss J. 2000
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Bedri A., Gudetta B., Isehak A., Kumbi S., Lulseged S., Mengistu Y., Bhore AV., Bhosale R., Varadhrajan V., Gupte N., Sastry J., Suryavanshi N., Tripathy S., Mmiro F., Mubiru M., Onyango C., Taylor A., Musoke P., Nakabiito C., Abashawl A., Adamu R., Antelman G., Bollinger RC., Bright P., Chaudhary MA., Coberly J., Guay L., Fowler MG., Gupta A., Hassen E., Jackson JB., Moulton LH., Nayak U., Omer SB., Propper L., Ram M., Rexroad V., Ruff AJ., Shankar A., Zwerski S. 2008
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. Thior I., Lockman S., Smeaton LM., Shapiro RL., Wester C., Heymann SJ., Gilbert PB., Stevens L., Peter T., Kim S., van Widenfelt E., Moffat C., Ndase P., Arimi P., Kebaabetswe P., Mazonde P., Makhema J., McIntosh K., Novitsky V., Lee TH., Marlink R., Lagakos S., Essex M. 2006
Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. Gregson S., Adamson S., Papaya S., Mundondo J., Nyamukapa CA., Mason PR., Garnett GP., Chandiwana SK., Foster G., Anderson RM. 2007
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Grosskurth H., Mosha F., Todd J., Mwijarubi E., Klokke A., Senkoro K., Mayaud P., Changalucha J., Nicoll A., ka-Gina G. 1995
Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Kamali A., Quigley M., Nakiyingi J., Kinsman J., Kengeya-Kayondo J., Gopal R., Ojwiya A., Hughes P., Carpenter LM., Whitworth J. 2003
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Wawer MJ., Sewankambo NK., Serwadda D., Quinn TC., Paxton LA., Kiwanuka N., Wabwire-Mangen F., Li C., Lutalo T., Nalugoda F., Gaydos CA., Moulton LH., Meehan MO., Ahmed S., Gray RH. 1999
Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Bobat R., Coovadia H., Stephen C., Naidoo KL., McKerrow N., Black RE., Moss WJ. 2005
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Chintu C., Bhat GJ., Walker AS., Mulenga V., Sinyinza F., Lishimpi K., Farrelly L., Kaganson N., Zumla A., Gillespie SH., Nunn AJ., Gibb DM. -- Not Found --
The effects of vitamin A supplementation on the morbidity of children born to HIV-infected women. Coutsoudis A., Bobat RA., Coovadia HM., Kuhn L., Tsai WY., Stein ZA. 1995
Routinely available cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to HIV-infected mothers in South Africa. Coutsoudis A., Pillay K., Spooner E., Coovadia HM., Pembrey L., Newell ML. 2005
A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Fawzi WW., Mbise RL., Hertzmark E., Fataki MR., Herrera MG., Ndossi G., Spiegelman D. 1999
Zinc or multiple micronutrient supplementation to reduce diarrhea and respiratory disease in South African children: a randomized controlled trial. Luabeya KK., Mpontshane N., Mackay M., Ward H., Elson I., Chhagan M., Tomkins A., Van den Broeck J., Bennish ML. 2007
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Mermin J., Lule J., Ekwaru JP., Malamba S., Downing R., Ransom R., Kaharuza F., Culver D., Kizito F., Bunnell R., Kigozi A., Nakanjako D., Wafula W., Quick R. -- Not Found --
Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virus-infected children in Uganda: A controlled clinical trial. Semba RD., Ndugwa C., Perry RT., Clark TD., Jackson JB., Melikian G., Tielsch J., Mmiro F. 2005
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Jaffar S., Amuron B., Foster S., Birungi J., Levin J., Namara G., Nabiryo C., Ndembi N., Kyomuhangi R., Opio A., Bunnell R., Tappero JW., Mermin J., Coutinho A., Grosskurth H. 2009
Task-shifting of antiretroviral delivery from health care workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya. Selke HM., Kimaiyo S., Sidle JE., Vedanthan R., Tierney WM., Shen C., Denski CD., Katschke AR., Wools-Kaloustian K. 2010
Primary care for patients infected with human immunodeficiency virus: a randomized controlled trial. Keitz SA., Box TL., Homan RK., Bartlett JA., Oddone EZ. 2001
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. Megazzini KM., Sinkala M., Vermund SH., Redden DT., Krebs DW., Acosta EP., Mwanza J., Goldenberg RL., Chintu N., Bulterys M., Stringer JS. 2010
A traditional healers' training model in rural Nepal: strengthening their roles in community health. Poudyal AK., Jimba M., Murakami I., Silwal RC., Wakai S., Kuratsuji T. 2003
Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients. Berneis K., Battegay M., Bassetti S., Nuesch R., Leisibach A., Bilz S., Keller U. 2000
Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. Clark RH., Feleke G., Din M., Yasmin T., Singh G., Khan FA., Rathmacher JA. -- Not Found --
L-ornithine alpha-ketoglutarate in HIV infection: effects on muscle, gastrointestinal, and immune functions. Karsegard VL., Raguso CA., Genton L., Hirschel B., Pichard C. 2004
Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. Keithley JK., Swanson B., Zeller JM., Sha BE., Cohen M., Hershow R., Novak R. -- Not Found --
Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Moreno YF., Sgarbieri VC., da Silva MN., Toro AA., Vilela MM. 2006
A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients. Rabeneck L., Palmer A., Knowles JB., Seidehamel RJ., Harris CL., Merkel KL., Risser JM., Akrabawi SS. 1998
The effect of nutritional support on weight gain of HIV-infected children with prolonged diarrhoea. Rollins NC., van den Broeck J., Kindra G., Pent M., Kasambira T., Bennish ML. 2007
Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Shabert JK., Winslow C., Lacey JM., Wilmore DW. -- Not Found --
Nutrition rehabilitation of HIV-infected and HIV-negative undernourished children utilizing spirulina. Simpore J., Zongo F., Kabore F., Dansou D., Bere A., Nikiema JB., Pignatelli S., Biondi DM., Ruberto G., Musumeci S. -- Not Found --
Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV-tuberculosis coinfection receiving directly observed short-course chemotherapy for tuberculosis. Sudarsanam TD., John J., Kang G., Mahendri V., Gerrior J., Franciosa M., Gopal S., John KR., Wanke CA., Muliyil J. 2011
Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors. Naar-King S., Parsons JT., Murphy DA., Chen X., Harris DR., Belzer ME. 2009
Healthy choices: motivational enhancement therapy for health risk behaviors in HIV-positive youth. Naar-King S., Wright K., Parsons JT., Frey M., Templin T., Lam P., Murphy D. 2006
Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Fawzi WW., Msamanga GI., Spiegelman D., Urassa EJ., McGrath N., Mwakagile D., Antelman G., Mbise R., Herrera G., Kapiga S., Willett W., Hunter DJ. 1998
Trial of zinc supplements in relation to pregnancy outcomes, hematologic indicators, and T cell counts among HIV-1-infected women in Tanzania. Fawzi WW., Villamor E., Msamanga GI., Antelman G., Aboud S., Urassa W., Hunter D. 2005
A randomized trial to determine the optimal dosage of multivitamin supplements to reduce adverse pregnancy outcomes among HIV-infected women in Tanzania. Kawai K., Kupka R., Mugusi F., Aboud S., Okuma J., Villamor E., Spiegelman D., Fawzi WW. 2010
Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes. Kupka R., Mugusi F., Aboud S., Msamanga GI., Finkelstein JL., Spiegelman D., Fawzi WW. 2008
Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Allard JP., Aghdassi E., Chau J., Tam C., Kovacs CM., Salit IE., Walmsley SL. 1998
Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Arpadi SM., McMahon D., Abrams EJ., Bamji M., Purswani M., Engelson ES., Horlick M., Shane E. 2009
A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome. Austin J., Singhal N., Voigt R., Smaill F., Gill MJ., Walmsley S., Salit I., Gilmour J., Schlech WF., Choudhri S., Rachlis A., Cohen J., Trottier S., Toma E., Phillips P., Ford PM., Woods R., Singer J., Zarowny DP., Cameron DW. 2006
Vitamin A supplementation and human immunodeficiency virus type 1 shedding in women: results of a randomized clinical trial. Baeten JM., McClelland RS., Overbaugh J., Richardson BA., Emery S., Lavreys L., Mandaliya K., Bankson DD., Ndinya-Achola JO., Bwayo JJ., Kreiss JK. 2002
Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Bobat R., Coovadia H., Stephen C., Naidoo KL., McKerrow N., Black RE., Moss WJ. 2005
Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. Burbano X., Miguez-Burbano MJ., McCollister K., Zhang G., Rodriguez A., Ruiz P., Lecusay R., Shor-Posner G. -- Not Found --
Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV-1 infection. Cárcamo C., Hooton T., Weiss NS., Gilman R., Wener MH., Chavez V., Meneses R., Echevarria J., Vidal M., Holmes KK. 2006
Beta-carotene in HIV infection. Coodley GO., Nelson HD., Loveless MO., Folk C. 1993
Beta-carotene in HIV infection: an extended evaluation. Coodley GO., Coodley MK., Lusk R., Green TR., Bakke AC., Wilson D., Wachenheim D., Sexton G., Salveson C. 1996
Effect of vitamin A therapy on serologic responses and viral load changes after influenza vaccination in children infected with the human immunodeficiency virus. Hanekom WA., Yogev R., Heald LM., Edwards KM., Hussey GD., Chadwick EG. 2000
Short-term effects of large-dose vitamin A supplementation on viral load and immune response in HIV-infected women. Humphrey JH., Quinn T., Fine D., Lederman H., Yamini-Roodsari S., Wu LS., Moeller S., Ruff AJ. 1999
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Hurwitz BE., Klaus JR., Llabre MM., Gonzalez A., Lawrence PJ., Maher KJ., Greeson JM., Baum MK., Shor-Posner G., Skyler JS., Schneiderman N. 2007
A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV-infected individuals living in Bangkok. Jiamton S., Pepin J., Suttent R., Filteau S., Mahakkanukrauh B., Hanshaoworakul W., Chaisilwattana P., Suthipinittharm P., Shetty P., Jaffar S. 2003
Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. Kaiser JD., Campa AM., Ondercin JP., Leoung GS., Pless RF., Baum MK. 2006
Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial. Kelly P., Musonda R., Kafwembe E., Kaetano L., Keane E., Farthing M. 1999
Vitamin A supplementation and human immunodeficiency virus load in injection drug users. Semba RD., Lyles CM., Margolick JB., Caiaffa WT., Farzadegan H., Cohn S., Vlahov D. 1998
Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. Semba RD., Ricketts EP., Mehta S., Netski D., Thomas D., Kirk G., Wu AW., Vlahov D. 2007
Micronutrient supplements and mortality of HIV-infected adults with pulmonary TB: a controlled clinical trial. Semba RD., Kumwenda J., Zijlstra E., Ricks MO., van Lettow M., Whalen C., Clark TD., Jorgensen L., Kohler J., Kumwenda N., Taha TE., Harries AD. 2007
A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. Villamor E., Mugusi F., Urassa W., Bosch RJ., Saathoff E., Matsumoto K., Meydani SN., Fawzi WW. 2008
Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Wejse C., Gomes VF., Rabna P., Gustafson P., Aaby P., Lisse IM., Andersen PL., Glerup H., Sodemann M. 2009
Effectiveness of a home-based exercise intervention for HIV-infected adults: a randomized trial. Baigis J., Korniewicz DM., Chase G., Butz A., Jacobson D., Wu AW. -- Not Found --
Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Dolan SE., Frontera W., Librizzi J., Ljungquist K., Juan S., Dorman R., Cole ME., Kanter JR., Grinspoon S. 2006
Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. Driscoll SD., Meininger GE., Lareau MT., Dolan SE., Killilea KM., Hadigan CM., Lloyd-Jones DM., Klibanski A., Frontera WR., Grinspoon SK. 2004
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Grinspoon S., Corcoran C., Parlman K., Costello M., Rosenthal D., Anderson E., Stanley T., Schoenfeld D., Burrows B., Hayden D., Basgoz N., Klibanski A. 2000
Exercise intervention attenuates emotional distress and natural killer cell decrements following notification of positive serologic status for HIV-1. LaPerriere AR., Antoni MH., Schneiderman N., Ironson G., Klimas N., Caralis P., Fletcher MA. 1990
Aerobic and resistance exercise training effects on body composition, muscular strength, and cardiovascular fitness in an HIV-1 population. Lox CL., McAuley E., Tucker RS. 1996
Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. MacArthur RD., Levine SD., Birk TJ. 1993
The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Mutimura E., Stewart A., Crowther NJ., Yarasheski KE., Cade WT. 2008
The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Stringer WW., Berezovskaya M., O'Brien WA., Beck CK., Casaburi R. 1998
Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. Berrien VM., Salazar JC., Reynolds E., McKay K. 2004
Impact of a patient-centered, computer-based health information/support system. Gustafson DH., Hawkins R., Boberg E., Pingree S., Serlin RE., Graziano F., Chan CL. 1999
Effect of home-based water chlorination and safe storage on diarrhea among persons with human immunodeficiency virus in Uganda. Lule JR., Mermin J., Ekwaru JP., Malamba S., Downing R., Ransom R., Nakanjako D., Wafula W., Hughes P., Bunnell R., Kaharuza F., Coutinho A., Kigozi A., Quick R. 2005
Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. The French Multicenter Total Parenteral Nutrition Cooperative Group Study. Melchior JC., Chastang C., Gelas P., Carbonnel F., Zazzo JF., Boulier A., Cosnes J., Boulétreau P., Messing B. 1996
An HIV self-care symptom management intervention for African American mothers. Miles MS., Holditch-Davis D., Eron J., Black BP., Pedersen C., Harris DA. -- Not Found --
Quality of life in nurse case management of persons with AIDS receiving home care. Nickel JT., Salsberry PJ., Caswell RJ., Keller MD., Long T., O'Connell M. 1996
Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. Williams AB., Fennie KP., Bova CA., Burgess JD., Danvers KA., Dieckhaus KD. 2006
The effects of massage therapy alone and in combination with other complementary therapies on immune system measures and quality of life in human immunodeficiency virus. Birk TJ., McGrady A., MacArthur RD., Khuder S. 2000
HIV adolescents show improved immune function following massage therapy. Diego MA., Field T., Hernandez-Reif M., Shaw K., Friedman L., Ironson G. 2001
Impact of a massage therapy clinical trial on immune status in young Dominican children infected with HIV-1. Shor-Posner G., Hernandez-Reif M., Miguez MJ., Fletcher M., Quintero N., Baez J., Perez-Then E., Soto S., Mendoza R., Castillo R., Zhang G. -- Not Found --
A randomized controlled trial of meditation and massage effects on quality of life in people with late-stage disease: a pilot study. Williams AL., Selwyn PA., Liberti L., Molde S., Njike VY., McCorkle R., Zelterman D., Katz DL. 2005
Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. Bhasin S., Storer TW., Asbel-Sethi N., Kilbourne A., Hays R., Sinha-Hikim I., Shen R., Arver S., Beall G. 1998
Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. Choi HH., Gray PB., Storer TW., Calof OM., Woodhouse L., Singh AB., Padero C., Mac RP., Sinha-Hikim I., Shen R., Dzekov J., Dzekov C., Kushnir MM., Rockwood AL., Meikle AW., Lee ML., Hays RD., Bhasin S. 2005
A trial of testosterone therapy for HIV-associated weight loss. Coodley GO., Coodley MK. 1997
The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Dobs AS., Cofrancesco J., Nolten WE., Danoff A., Anderson R., Hamilton CD., Feinberg J., Seekins D., Yangco B., Rhame F. 1999
Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Dolan S., Wilkie S., Aliabadi N., Sullivan MP., Basgoz N., Davis B., Grinspoon S. 2004
Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Grinspoon S., Corcoran C., Askari H., Schoenfeld D., Wolf L., Burrows B., Walsh M., Hayden D., Parlman K., Anderson E., Basgoz N., Klibanski A. 1998
Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. Hengge UR., Stocks K., Wiehler H., Faulkner S., Esser S., Lorenz C., Jentzen W., Hengge D., Goos M., Dudley RE., Ringham G. 2003
Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. Miller K., Corcoran C., Armstrong C., Caramelli K., Anderson E., Cotton D., Basgoz N., Hirschhorn L., Tuomala R., Schoenfeld D., Daugherty C., Mazer N., Grinspoon S. 1998
Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Mulligan K., Zackin R., Clark RA., Alston-Smith B., Liu T., Sattler FR., Delvers TB., Currier JS. 2005
Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. Strawford A., Barbieri T., Van Loan M., Parks E., Catlin D., Barton N., Neese R., Christiansen M., King J., Hellerstein MK. 1999
Effects of whey protein and resistance exercise on body cell mass, muscle strength, and quality of life in women with HIV. Agin D., Gallagher D., Wang J., Heymsfield SB., Pierson RN., Kotler DP. 2001
Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. Sattler FR., Jaque SV., Schroeder ET., Olson C., Dube MP., Martinez C., Briggs W., Horton R., Azen S. 1999
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lester RT., Ritvo P., Mills EJ., Kariri A., Karanja S., Chung MH., Jack W., Habyarimana J., Sadatsafavi M., Najafzadeh M., Marra CA., Estambale B., Ngugi E., Ball TB., Thabane L., Gelmon LJ., Kimani J., Ackers M., Plummer FA. 2010
Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. Pop-Eleches C., Thirumurthy H., Habyarimana JP., Zivin JG., Goldstein MP., de Walque D., MacKeen L., Haberer J., Kimaiyo S., Sidle J., Ngare D., Bangsberg DR. 2011
Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial. Wamalwa DC., Farquhar C., Obimbo EM., Selig S., Mbori-Ngacha DA., Richardson BA., Overbaugh J., Egondi T., Inwani I., John-Stewart G. 2009
Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. DiIorio C., Resnicow K., McDonnell M., Soet J., McCarty F., Yeager K. -- Not Found --
Randomized trial of an adherence programme for clients with HIV. Fairley CK., Levy R., Rayner CR., Allardice K., Costello K., Thomas C., McArthur C., Kong D., Mijch A., -- 2003
Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. Goujard C., Bernard N., Sohier N., Peyramond D., Lançon F., Chwalow J., Arnould B., Delfraissy JF. 2003
Influencing medication adherence among women with AIDS. Jones DL., Ishii M., LaPerriere A., Stanley H., Antoni M., Ironson G., Schneiderman N., Van Splunteren F., Cassells A., Alexander K., Gousse YP., Vaughn A., Brondolo E., Tobin JN., Weiss SM. 2003
Multidisciplinary HIV adherence intervention: a randomized study. Levy RW., Rayner CR., Fairley CK., Kong DC., Mijch A., Costello K., McArthur C. 2004
Results of a pilot intervention trial to improve antiretroviral adherence among HIV-positive patients. Murphy DA., Lu MC., Martin D., Hoffman D., Marelich WD. -- Not Found --
Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. Pradier C., Bentz L., Spire B., Tourette-Turgis C., Morin M., Souville M., Rebillon M., Fuzibet JG., Pesce A., Dellamonica P., Moatti JP. -- Not Found --
Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Rathbun RC., Farmer KC., Stephens JR., Lockhart SM. 2005
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. Rawlings MK., Thompson MA., Farthing CF., Brown LS., Racine J., Scott RC., Crawford KH., Goodwin SD., Tolson JM., Williams VC., Shaefer MS. 2003
Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Safren SA., Otto MW., Worth JL., Salomon E., Johnson W., Mayer K., Boswell S. 2001
Use of an on-line pager system to increase adherence to antiretroviral medications. Safren SA., Hendriksen ES., Desousa N., Boswell SL., Mayer KH. 2003
A medication self-management program to improve adherence to HIV therapy regimens. Smith SR., Rublein JC., Marcus C., Brock TP., Chesney MA. 2003
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. Tuldrà A., Fumaz CR., Ferrer MJ., Bayés R., Arnó A., Balagué M., Bonjoch A., Jou A., Negredo E., Paredes R., Ruiz L., Romeu J., Sirera G., Tural C., Burger D., Clotet B. 2000
Program to enhance health literacy and treatment adherence in low-income HIV-infected Latino men and women. van Servellen G., Carpio F., Lopez M., Garcia-Teague L., Herrera G., Monterrosa F., Gomez R., Lombardi E. 2003
Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Weber R., Christen L., Christen S., Tschopp S., Znoj H., Schneider C., Schmitt J., Opravil M., Günthard HF., Ledergerber B. 2004
The efficacy of an integrated risk reduction intervention for HIV-positive women with child sexual abuse histories. Wyatt GE., Longshore D., Chin D., Carmona JV., Loeb TB., Myers HF., Warda U., Liu H., Rivkin I. 2004
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. Gulick RM., Ribaudo HJ., Shikuma CM., Lustgarten S., Squires KE., Meyer WA., Acosta EP., Schackman BR., Pilcher CD., Murphy RL., Maher WE., Witt MD., Reichman RC., Snyder S., Klingman KL., Kuritzkes DR. 2004
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. Kumar PN., Rodriguez-French A., Thompson MA., Tashima KT., Averitt D., Wannamaker PG., Williams VC., Shaefer MS., Pakes GE., Pappa KA. 2006
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). Kumar PN., Salvato P., Lamarca A., Dejesus E., Patel P., McClernon D., Florance A., Shaefer MS. 2009
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. Shapiro RL., Hughes MD., Ogwu A., Kitch D., Lockman S., Moffat C., Makhema J., Moyo S., Thior I., McIntosh K., van Widenfelt E., Leidner J., Powis K., Asmelash A., Tumbare E., Zwerski S., Sharma U., Handelsman E., Mburu K., Jayeoba O., Moko E., Souda S., Lubega E., Akhtar M., Wester C., Tuomola R., Snowden W., Martinez-Tristani M., Mazhani L., Essex M. 2010
Final analysis of the Trilège induction-maintenance trial: results at 18 months. Flandre P., Raffi F., Descamps D., Calvez V., Peytavin G., Meiffredy V., Harel M., Hazebrouck S., Pialoux G., Aboulker JP., Brun Vezinet F. 2002
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. Havlir DV., Marschner IC., Hirsch MS., Collier AC., Tebas P., Bassett RL., Ioannidis JP., Holohan MK., Leavitt R., Boone G., Richman DD. 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Reijers MH., Weverling GJ., Jurriaans S., Wit FW., Weigel HM., Ten Kate RW., Mulder JW., Frissen PH., van Leeuwen R., Reiss P., Schuitemaker H., de Wolf F., Lange JM. 1998
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. French M., Amin J., Roth N., Carr A., Law M., Emery S., Drummond F., Cooper D. -- Not Found --
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo UG., van der Westhuizen IP., Malan DR., Johnson MA., Santos BR., Mulcahy F., Wood R., Levi GC., Reboredo G., Squires K., Cassetti I., Petit D., Raffi F., Katlama C., Murphy RL., Horban A., Dam JP., Hassink E., van Leeuwen R., Robinson P., Wit FW., Lange JM. 2004
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Manosuthi W., Sungkanuparph S., Tantanathip P., Lueangniyomkul A., Mankatitham W., Prasithsirskul W., Burapatarawong S., Thongyen S., Likanonsakul S., Thawornwa U., Prommool V., Ruxrungtham K. 2009
SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. Núñez M., Soriano V., Martín-Carbonero L., Barrios A., Barreiro P., Blanco F., García-Benayas T., González-Lahoz J. -- Not Found --
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. van den Berg-Wolf M., Hullsiek KH., Peng G., Kozal MJ., Novak RM., Chen L., Crane LR., Macarthur RD. -- Not Found --
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. Carr A., Chuah J., Hudson J., French M., Hoy J., Law M., Sayer D., Emery S., Cooper DA. 2000
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Eron JJ., Murphy RL., Peterson D., Pottage J., Parenti DM., Jemsek J., Swindells S., Sepulveda G., Bellos N., Rashbaum BC., Esinhart J., Schoellkopf N., Grosso R., Stevens M. 2000
Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. Gathe J., Badaro R., Grimwood A., Abrams L., Klesczewski K., Cross A., McLaren C. 2002
Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. Li T., Dai Y., Kuang J., Jiang J., Han Y., Qiu Z., Xie J., Zuo L., Li Y. 2008
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. Robbins GK., De Gruttola V., Shafer RW., Smeaton LM., Snyder SW., Pettinelli C., Dubé MP., Fischl MA., Pollard RB., Delapenha R., Gedeon L., van der Horst C., Murphy RL., Becker MI., D'Aquila RT., Vella S., Merigan TC., Hirsch MS. 2003
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Squires KE., Gulick R., Tebas P., Santana J., Mulanovich V., Clark R., Yangco B., Marlowe SI., Wright D., Cohen C., Cooley T., Mauney J., Uffelman K., Schoellkopf N., Grosso R., Stevens M. 2000
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Fox Z., Dragsted UB., Gerstoft J., Phillips AN., Kjaer J., Mathiesen L., Youle M., Katlama C., Hill A., Bruun JN., Clumeck N., Dellamonica P., Lundgren JD. 2006
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. Pujades-Rodríguez M., O'Brien D., Humblet P., Calmy A. 2008
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE., DeJesus E., Arribas JR., Pozniak AL., Gazzard B., Campo RE., Lu B., McColl D., Chuck S., Enejosa J., Toole JJ., Cheng AK. 2006
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Rey D., Hoen B., Chavanet P., Schmitt MP., Hoizey G., Meyer P., Peytavin G., Spire B., Allavena C., Diemer M., May T., Schmit JL., Duong M., Calvez V., Lang JM. 2009
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. Bae WH., Wester C., Smeaton LM., Shapiro RL., Lockman S., Onyait K., Thior I., Essex M. 2008
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. Ekouevi DK., Coffie PA., Becquet R., Tonwe-Gold B., Horo A., Thiebaut R., Leroy V., Blanche S., Dabis F., Abrams EJ. 2008
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. Jamisse L., Balkus J., Hitti J., Gloyd S., Manuel R., Osman N., Djedje M., Farquhar C. 2007
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. Lehman DA., Chung MH., John-Stewart GC., Richardson BA., Kiarie J., Kinuthia J., Overbaugh J. 2008
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. Phanuphak N., Apornpong T., Teeratakulpisarn S., Chaithongwongwatthana S., Taweepolcharoen C., Mangclaviraj S., Limpongsanurak S., Jadwattanakul T., Eiamapichart P., Luesomboon W., Apisarnthanarak A., Kamudhamas A., Tangsathapornpong A., Vitavasiri C., Singhakowinta N., Attakornwattana V., Kriengsinyot R., Methajittiphun P., Chunloy K., Preetiyathorn W., Aumchantr T., Toro P., Abrams EJ., El-Sadr W., Phanuphak P. 2007
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. Tonwe-Gold B., Ekouevi DK., Viho I., Amani-Bosse C., Toure S., Coffie PA., Rouet F., Becquet R., Leroy V., El-Sadr WM., Abrams EJ., Dabis F. 2007
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. Bonjoch A., Paredes R., Galvez J., Miralles C., Videla S., Martínez E., Miranda J., Muñoz-Moreno JA., De la Torre J., Prieto A., Vilades C., Clotet B. 2005
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. Clumeck N., Goebel F., Rozenbaum W., Gerstoft J., Staszewski S., Montaner J., Johnson M., Gazzard B., Stone C., Athisegaran R., Moore S. 2001
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. Katlama C., Fenske S., Gazzard B., Lazzarin A., Clumeck N., Mallolas J., Lafeuillade A., Mamet JP., Beauvais L. 2003
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. Keiser PH., Sension MG., DeJesus E., Rodriguez A., Olliffe JF., Williams VC., Wakeford JH., Snidow JW., Shachoy-Clark AD., Fleming JW., Pakes GE., Hernandez JE. 2005
Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Maggiolo F., Ripamonti D., Ravasio L., Gregis G., Quinzan G., Callegaro A., Arici C., Suter F. 2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. Martínez E., Arnaiz JA., Podzamczer D., Dalmau D., Ribera E., Domingo P., Knobel H., Riera M., Pedrol E., Force L., Llibre JM., Segura F., Richart C., Cortés C., Javaloyas M., Aranda M., Cruceta A., de Lazzari E., Gatell JM. 2003
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. Opravil M., Hirschel B., Lazzarin A., Furrer H., Chave JP., Yerly S., Bisset LR., Fischer M., Vernazza P., Bernasconi E., Battegay M., Ledergerber B., Günthard H., Howe C., Weber R., Perrin L. 2002
Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. Sprenger HG., Langebeek N., Mulder PG., Ten Napel CH., Vriesendorp R., Hoepelman AI., Legrand JC., Koopmans PP., Van Kasteren ME., Bravenboer B., Ten Kate RW., Groeneveld PH., van der Werf TS., Gisolf EH., Richter C. 2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. Coovadia A., Abrams EJ., Stehlau R., Meyers T., Martens L., Sherman G., Hunt G., Hu CC., Tsai WY., Morris L., Kuhn L. 2010
Antiretroviral treatment for children with peripartum nevirapine exposure. Palumbo P., Lindsey JC., Hughes MD., Cotton MF., Bobat R., Meyers T., Bwakura-Dangarembizi M., Chi BH., Musoke P., Kamthunzi P., Schimana W., Purdue L., Eshleman SH., Abrams EJ., Millar L., Petzold E., Mofenson LM., Jean-Philippe P., Violari A. 2010
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. Prendergast A., Mphatswe W., Tudor-Williams G., Rakgotho M., Pillay V., Thobakgale C., McCarthy N., Morris L., Walker BD., Goulder P. 2008
Early antiretroviral therapy and mortality among HIV-infected infants. Violari A., Cotton MF., Gibb DM., Babiker AG., Steyn J., Madhi SA., Jean-Philippe P., McIntyre JA. 2008
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. Jacobson JM., Saag MS., Thompson MA., Fischl MA., Liporace R., Reichman RC., Redfield RR., Fichtenbaum CJ., Zingman BS., Patel MC., Murga JD., Pemrick SM., D'Ambrosio P., Michael M., Kroger H., Ly H., Rotshteyn Y., Buice R., Morris SA., Stavola JJ., Maddon PJ., Kremer AB., Olson WC. 2008
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Jacobson JM., Thompson MA., Lalezari JP., Saag MS., Zingman BS., D'Ambrosio P., Stambler N., Rotshteyn Y., Marozsan AJ., Maddon PJ., Morris SA., Olson WC. 2010
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Volberding PA., Lagakos SW., Koch MA., Pettinelli C., Myers MW., Booth DK., Balfour HH., Reichman RC., Bartlett JA., Hirsch MS. 1990
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. Volberding PA., Lagakos SW., Grimes JM., Stein DS., Rooney J., Meng TC., Fischl MA., Collier AC., Phair JP., Hirsch MS. 1995
Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Merigan TC., Amato DA., Balsley J., Power M., Price WA., Benoit S., Perez-Michael A., Brownstein A., Kramer AS., Brettler D. 1991
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. -- Not Found -- 1994
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Mannucci PM., Gringeri A., Savidge G., Gatenby P., Laurian Y., Pabinger-Fasching I., Martinez-Vazquez JM., Hessey EW., Steel HM. 1994
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017) Mulder JW., Cooper DA., Mathiesen L., Sandström E., Clumeck N., Gatell JM., French M., Donovan B., Gray F., Yeo JM. 1994
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. Cooper DA., Gatell JM., Kroon S., Clumeck N., Millard J., Goebel FD., Bruun JN., Stingl G., Melville RL., González-Lahoz J. 1993
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Fischl MA., Stanley K., Collier AC., Arduino JM., Stein DS., Feinberg JE., Allan JD., Goldsmith JC., Powderly WG. 1995
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. Hammer SM., Katzenstein DA., Hughes MD., Gundacker H., Schooley RT., Haubrich RH., Henry WK., Lederman MM., Phair JP., Niu M., Hirsch MS., Merigan TC. 1996
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. Henry K., Erice A., Tierney C., Balfour HH., Fischl MA., Kmack A., Liou SH., Kenton A., Hirsch MS., Phair J., Martinez A., Kahn JO. 1998
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Saravolatz LD., Winslow DL., Collins G., Hodges JS., Pettinelli C., Stein DS., Markowitz N., Reves R., Loveless MO., Crane L., Thompson M., Abrams D. 1996
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. -- Not Found -- 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. Schooley RT., Ramirez-Ronda C., Lange JM., Cooper DA., Lavelle J., Lefkowitz L., Moore M., Larder BA., St Clair M., Mulder JW., McKinnis R., Pennington KN., Harrigan PR., Kinghorn I., Steel H., Rooney JF. 1996
Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. Alexander TH., Ortiz GM., Wellons MF., Allen A., Grace EJ., Schweighardt B., Brancato J., Sandberg JK., Furlan SN., Miralles GD., Nixon DF., Bartlett JA. 2003
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. Ananworanich J., Nuesch R., Le Braz M., Chetchotisakd P., Vibhagool A., Wicharuk S., Ruxrungtham K., Furrer H., Cooper D., Hirschel B., Bernasconi E., Cavassini M., Ebnöther C., Fagard C., Genné D., Khanna N., Perrin L., Phanupak P., Ubolyam S., Vernazza P., Yerly S. 2003
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Cardiello PG., Hassink E., Ananworanich J., Srasuebkul P., Samor T., Mahanontharit A., Ruxrungtham K., Hirschel B., Lange J., Phanuphak P., Cooper DA. 2005
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Dybul M., Chun TW., Yoder C., Hidalgo B., Belson M., Hertogs K., Larder B., Dewar RL., Fox CH., Hallahan CW., Justement JS., Migueles SA., Metcalf JA., Davey RT., Daucher M., Pandya P., Baseler M., Ward DJ., Fauci AS. 2001
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. Florence E., García F., Plana M., Fumero E., Castro P., Lopez A., Cruceta A., Gil C., Arnedo M., Miró JM., Pumarola T., Gallart T., Gatell JM. 2004
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. García F., Plana M., Arnedo M., Ortiz GM., Miró JM., Lopalco L., Lori F., Pumarola T., Gallart T., Gatell JM. 2003
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., Suter F. 2004
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Nuesch R., Ananworanich J., Sirivichayakul S., Ubolyam S., Siangphoe U., Hill A., Cooper D., Lange J., Phanuphak P., Ruxrungtham K. 2005
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. Papasavvas E., Kostman JR., Mounzer K., Grant RM., Gross R., Gallo C., Azzoni L., Foulkes A., Thiel B., Pistilli M., Mackiewicz A., Shull J., Montaner LJ. 2004
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. Plana M., Garcia F., Oxenius A., Ortiz GM., Lopez A., Cruceta A., Mestre G., Fumero E., Fagard C., Sambeat MA., Segura F., Miró JM., Arnedo M., Lopalcos L., Pumarola T., Hirschel B., Phillips RE., Nixon DF., Gallart T., Gatell JM. 2004
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. Ruiz L., Martinez-Picado J., Romeu J., Paredes R., Zayat MK., Marfil S., Negredo E., Sirera G., Tural C., Clotet B. 2000
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. Deeks SG., Wrin T., Liegler T., Hoh R., Hayden M., Barbour JD., Hellmann NS., Petropoulos CJ., McCune JM., Hellerstein MK., Grant RM. 2001
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. Ruiz L., Ribera E., Bonjoch A., Romeu J., Martinez-Picado J., Paredes R., Díaz M., Marfil S., Negredo E., García-Prado J., Tural C., Sirera G., Clotet B. 2003
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). Katlama C., Dominguez S., Gourlain K., Duvivier C., Delaugerre C., Legrand M., Tubiana R., Reynes J., Molina JM., Peytavin G., Calvez V., Costagliola D. 2004
Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Makadzange AT., Ndhlovu CE., Takarinda K., Reid M., Kurangwa M., Gona P., Hakim JG. 2010
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. Zolopa A., Andersen J., Powderly W., Sanchez A., Sanne I., Suckow C., Hogg E., Komarow L. 2009
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. Emery S., Neuhaus JA., Phillips AN., Babiker A., Cohen CJ., Gatell JM., Girard PM., Grund B., Law M., Losso MH., Palfreeman A., Wood R. 2008
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Abrams DI., Hilton JF., Leiser RJ., Shade SB., Elbeik TA., Aweeka FT., Benowitz NL., Bredt BM., Kosel B., Aberg JA., Deeks SG., Mitchell TF., Mulligan K., Bacchetti P., McCune JM., Schambelan M. 2003
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Abrams DI., Jay CA., Shade SB., Vizoso H., Reda H., Press S., Kelly ME., Rowbotham MC., Petersen KL. 2007
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Beal JE., Olson R., Laubenstein L., Morales JO., Bellman P., Yangco B., Lefkowitz L., Plasse TF., Shepard KV. 1995
Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Ellis RJ., Toperoff W., Vaida F., van den Brande G., Gonzales J., Gouaux B., Bentley H., Atkinson JH. 2009
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Haney M., Rabkin J., Gunderson E., Foltin RW. 2005
Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. Haney M., Gunderson EW., Rabkin J., Hart CL., Vosburg SK., Comer SD., Foltin RW. 2007
Effect of dronabinol on nutritional status in HIV infection. Struwe M., Kaempfer SH., Geiger CJ., Pavia AT., Plasse TF., Shepard KV., Ries K., Evans TG. -- Not Found --
Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. Burack JH., Cohen MR., Hahn JA., Abrams DI. 1996
Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial. Durant J., Chantre P., Gonzalez G., Vandermander J., Halfon P., Rousse B., Guédon D., Rahelinirina V., Chamaret S., Montagnier L., Dellamonica P. 1998
A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Holodniy M., Koch J., Mistal M., Schmidt JM., Khandwala A., Pennington JE., Porter SB. 1999
Topical capsaicin in the management of HIV-associated peripheral neuropathy. Paice JA., Ferrans CE., Lashley FR., Shott S., Vizgirda V., Pitrak D. 2000
Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals. Weber R., Christen L., Loy M., Schaller S., Christen S., Joyce CR., Ledermann U., Ledergerber B., Cone R., Lüthy R., Cohen MR. 1999
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. Best BM., Goicoechea M., Witt MD., Miller L., Daar ES., Diamond C., Tilles JG., Kemper CA., Larsen R., Holland DT., Sun S., Jain S., Wagner G., Capparelli EV., McCutchan JA., Haubrich RH. 2007
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. Bossi P., Peytavin G., Ait-Mohand H., Delaugerre C., Ktorza N., Paris L., Bonmarchand M., Cacace R., David DJ., Simon A., Lamotte C., Marcelin AG., Calvez V., Bricaire F., Costagliola D., Katlama C. 2004
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. Burger D., Hugen P., Reiss P., Gyssens I., Schneider M., Kroon F., Schreij G., Brinkman K., Richter C., Prins J., Aarnoutse R., Lange J. 2003
PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. Clevenbergh P., Garraffo R., Durant J., Dellamonica P. 2002
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Fletcher CV., Anderson PL., Kakuda TN., Schacker TW., Henry K., Gross CR., Brundage RC. 2002
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. Khoo SH., Lloyd J., Dalton M., Bonington A., Hart E., Gibbons S., Flegg P., Sweeney J., Wilkins EG., Back DJ. 2006
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Torti C., Quiros-Roldan E., Regazzi M., De Luca A., Mazzotta F., Antinori A., Ladisa N., Micheli V., Orani A., Patroni A., Villani P., Lo Caputo S., Moretti F., Di Giambenedetto S., Castelnuovo F., Maggi P., Tinelli C., Carosi G. 2005
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Schuman P., Capps L., Peng G., Vazquez J., el-Sadr W., Goldman AI., Alston B., Besch CL., Vaughn A., Thompson MA., Cobb MN., Kerkering T., Sobel JD. 1997
Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with HIV. Williams AB., Yu C., Tashima K., Burgess J., Danvers K. -- Not Found --
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Arathoon EG., Gotuzzo E., Noriega LM., Berman RS., DiNubile MJ., Sable CA. 2002
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Chavanet PY., Garry I., Charlier N., Caillot D., Kisterman JP., D'Athis M., Portier H. 1992
Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. de Repentigny L., Ratelle J. -- Not Found --
Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. De Wit S., Weerts D., Goossens H., Clumeck N. 1989
A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. De Wit S., Dupont B., Cartledge JD., Hawkins DA., Gazzard BG., Clumeck N., Denning DW. 1997
Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. De Wit S., O'Doherty E., De Vroey C., Clumeck N. -- Not Found --
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Goldman M., Cloud GA., Wade KD., Reboli AC., Fichtenbaum CJ., Hafner R., Sobel JD., Powderly WG., Patterson TF., Wheat LJ., Stein DK., Dismukes WE., Filler SG. 2005
Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Graybill JR., Vazquez J., Darouiche RO., Morhart R., Greenspan D., Tuazon C., Wheat LJ., Carey J., Leviton I., Hewitt RG., MacGregor RR., Valenti W., Restrepo M., Moskovitz BL. 1998
Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Graybill JR., Vazquez J., Darouiche RO., Morhart R., Greenspan D., Tuazon C., Wheat LJ., Carey J., Leviton I., Hewitt RG., MacGregor RR., Valenti W., Restrepo M., Moskovitz BL. 1998
Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group. Hernández-Sampelayo T. 1994
Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Just-Nübling G., Gentschew G., Meissner K., Odewald J., Staszewski S., Helm EB., Stille W. 1991
Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. Leen CL., Dunbar EM., Ellis ME., Mandal BK. 1990
Clinical trial: clotrimazole troche vs. itraconazole oral solution in the treatment of oral candidosis in AIDS patients. Linpiyawan R., Jittreprasert K., Sivayathorn A. 2000
Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. MacPhail LA., Hilton JF., Dodd CL., Greenspan D. 1996
Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. McKinsey DS., Wheat LJ., Cloud GA., Pierce M., Black JR., Bamberger DM., Goldman M., Thomas CJ., Gutsch HM., Moskovitz B., Dismukes WE., Kauffman CA. 1999
Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Murray PA., Koletar SL., Mallegol I., Wu J., Moskovitz BL. -- Not Found --
A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Phillips P., De Beule K., Frechette G., Tchamouroff S., Vandercam B., Weitner L., Hoepelman A., Stingl G., Clotet B. 1998
Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. Pons V., Greenspan D., Debruin M. 1993
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Pons V., Greenspan D., Lozada-Nur F., McPhail L., Gallant JE., Tunkel A., Johnson CC., McCarty J., Panzer H., Levenstein M., Barranco A., Green S. 1997
A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection. Redding SW., Farinacci GC., Smith JA., Fothergill AW., Rinaldi MG. -- Not Found --
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Revankar SG., Kirkpatrick WR., McAtee RK., Dib OP., Fothergill AW., Redding SW., Rinaldi MG., Hilsenbeck SG., Patterson TF. 1998
Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. Smith DE., Midgley J., Allan M., Connolly GM., Gazzard BG. 1991
Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Stevens DA., Greene SI., Lang OS. 1991
Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. Van Roey J., Haxaire M., Kamya M., Lwanga I., Katabira E. 2004
Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS. Vazquez JA., Zawawi AA. -- Not Found --
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Vazquez JA., Skiest DJ., Nieto L., Northland R., Sanne I., Gogate J., Greaves W., Isaacs R. 2006
Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbopogon citratus) and gentian violet. Wright SC., Maree JE., Sibanyoni M. 2009
Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., Kelly P. 2002
Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Hewitt RG., Yiannoutsos CT., Higgs ES., Carey JT., Geiseler PJ., Soave R., Rosenberg R., Vazquez GJ., Wheat LJ., Fass RJ., Antoninievic Z., Walawander AL., Flanigan TP., Bender JF. 2000
A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. McMeeking A., Borkowsky W., Klesius PH., Bonk S., Holzman RS., Lawrence HS. 1990
Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. Nord J., Ma P., DiJohn D., Tzipori S., Tacket CO. 1990
A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Rossignol JF., Hidalgo H., Feregrino M., Higuera F., Gomez WH., Romero JL., Padierna J., Geyne A., Ayers MS. -- Not Found --
Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. White AC., Chappell CL., Hayat CS., Kimball KT., Flanigan TP., Goodgame RW. 1994
Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. Wittenberg DF., Miller NM., van den Ende J. 1989
Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. Abrams DI., Mitchell TF., Child CC., Shiboski SC., Brosgart CL., Mass MM. 1993
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Fischl MA., Richman DD., Hansen N., Collier AC., Carey JT., Para MF., Hardy WD., Dolin R., Powderly WG., Allan JD. 1990
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. Crommentuyn KM., Huitema AD., Brinkman K., van der Ende ME., de Wolf F., Beijnen JH. 2005
Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. Benson CA., Williams PL., Cohn DL., Becker S., Hojczyk P., Nevin T., Korvick JA., Heifets L., Child CC., Lederman MM., Reichman RC., Powderly WG., Notario GF., Wynne BA., Hafner R. 2000
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Currier JS., Williams PL., Koletar SL., Cohn SE., Murphy RL., Heald AE., Hafner R., Bassily EL., Lederman HM., Knirsch C., Benson CA., Valdez H., Aberg JA., McCutchan JA. 2000
Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. El-Sadr WM., Burman WJ., Grant LB., Matts JP., Hafner R., Crane L., Zeh D., Gallagher B., Mannheimer SB., Martinez A., Gordin F. 2000
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. Havlir DV., Dubé MP., Sattler FR., Forthal DN., Kemper CA., Dunne MW., Parenti DM., Lavelle JP., White AC., Witt MD., Bozzette SA., McCutchan JA. 1996
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. Nightingale SD., Cameron DW., Gordin FM., Sullam PM., Cohn DL., Chaisson RE., Eron LJ., Sparti PD., Bihari B., Kaufman DL. 1993
Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Oldfield EC., Fessel WJ., Dunne MW., Dickinson G., Wallace MR., Byrne W., Chung R., Wagner KF., Paparello SF., Craig DB., Melcher G., Zajdowicz M., Williams RF., Kelly JW., Zelasky M., Heifets LB., Berman JD. 1998
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. Pierce M., Crampton S., Henry D., Heifets L., LaMarca A., Montecalvo M., Wormser GP., Jablonowski H., Jemsek J., Cynamon M., Yangco BG., Notario G., Craft JC. 1996
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Dannemann B., McCutchan JA., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. 1992
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Katlama C., De Wit S., O'Doherty E., Van Glabeke M., Clumeck N. 1996
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Torre D., Casari S., Speranza F., Donisi A., Gregis G., Poggio A., Ranieri S., Orani A., Angarano G., Chiodo F., Fiori G., Carosi G. 1998
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Zar HJ., Cotton MF., Strauss S., Karpakis J., Hussey G., Schaaf HS., Rabie H., Lombard CJ. 2007
A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. Bozzette SA., Sattler FR., Chiu J., Wu AW., Gluckstein D., Kemper C., Bartok A., Niosi J., Abramson I., Coffman J. 1990
Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. Gagnon S., Boota AM., Fischl MA., Baier H., Kirksey OW., La Voie L. 1990
Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) Montaner JS., Lawson LM., Levitt N., Belzberg A., Schechter MT., Ruedy J. 1990
Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. Nielsen TL., Eeftinck Schattenkerk JK., Jensen BN., Lundgren JD., Gerstoft J., van Steenwijk RP., Bentsen K., Frissen PH., Gaub J., Orholm M. 1992
A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. Walmsley S., Levinton C., Brunton J., Muradali D., Rappaport D., Bast M., Spence D., Salit I. 1995
A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Chariyalertsak S., Supparatpinyo K., Sirisanthana T., Nelson KE. 2002
A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. Chetchotisakd P., Sungkanuparph S., Thinkhamrop B., Mootsikapun P., Boonyaprawit P. 2004
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. Bozzette SA., Finkelstein DM., Spector SA., Frame P., Powderly WG., He W., Phillips L., Craven D., van der Horst C., Feinberg J. 1995
A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. Smith DE., Bell J., Johnson M., Youle M., Gazzard B., Tchamouroff S., Frechette G., Schlech W., Miller S., Spencer D., Seifert W., Peeters M., De Beule K. 2001
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Bonfanti P., Pusterla L., Parazzini F., Libanore M., Cagni AE., Franzetti M., Faggion I., Landonio S., Quirino T. 2000
Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. Leoung GS., Stanford JF., Giordano MF., Stein A., Torres RA., Giffen CA., Wesley M., Sarracco T., Cooper EC., Dratter V., Smith JJ., Frost KR. 2001
A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides. Straatmann A., Bahia F., Pedral-Sampaio D., Brites C. 2002
Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Marriott DJ., Jones PD., Hoy JF., Speed BR., Harkness JL. 1993
A randomized clinical trial of chlorhexidine in the maintenance of oral candidiasis-free period in HIV infection. Nittayananta W., DeRouen TA., Arirachakaran P., Laothumthut T., Pangsomboon K., Petsantad S., Vuddhakul V., Sriplung H., Jaruratanasirikul S., Martin MD. 2008
Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. Pagani JL., Chave JP., Casjka C., Glauser MP., Bille J. 2002
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Anglaret X., Chêne G., Attia A., Toure S., Lafont S., Combe P., Manlan K., N'Dri-Yoman T., Salamon R. 1999
Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. Fischl MA., Dickinson GM., La Voie L. 1988
Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. Maynart M., Lièvre L., Sow PS., Kony S., Gueye NF., Bassène E., Metro A., Ndoye I., Ba DS., Coulaud JP., Costagliola D. 2001
Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Wiktor SZ., Sassan-Morokro M., Grant AD., Abouya L., Karon JM., Maurice C., Djomand G., Ackah A., Domoua K., Kadio A., Yapi A., Combe P., Tossou O., Roels TH., Lackritz EM., Coulibaly D., De Cock KM., Coulibaly IM., Greenberg AE. 1999
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Chintu C., Bhat GJ., Walker AS., Mulenga V., Sinyinza F., Lishimpi K., Farrelly L., Kaganson N., Zumla A., Gillespie SH., Nunn AJ., Gibb DM. -- Not Found --
No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. Fitzgerald DW., Severe P., Joseph P., Mellon LR., Noel E., Johnson WD., Pape JW. 2001
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. Gordin FM., Matts JP., Miller C., Brown LS., Hafner R., John SL., Klein M., Vaughn A., Besch CL., Perez G., Szabo S., El-Sadr W. 1997
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. Gordin F., Chaisson RE., Matts JP., Miller C., de Lourdes Garcia M., Hafner R., Valdespino JL., Coberly J., Schechter M., Klukowicz AJ., Barry MA., O'Brien RJ. 2000
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Halsey NA., Coberly JS., Desormeaux J., Losikoff P., Atkinson J., Moulton LH., Contave M., Johnson M., Davis H., Geiter L., Johnson E., Huebner R., Boulos R., Chaisson RE. 1998
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. Hawken MP., Meme HK., Elliott LC., Chakaya JM., Morris JS., Githui WA., Juma ES., Odhiambo JA., Thiong'o LN., Kimari JN., Ngugi EN., Bwayo JJ., Gilks CF., Plummer FA., Porter JD., Nunn PP., McAdam KP. 1997
Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Mohammed A., Myer L., Ehrlich R., Wood R., Cilliers F., Maartens G. 2007
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. Mwinga A., Hosp M., Godfrey-Faussett P., Quigley M., Mwaba P., Mugala BN., Nyirenda O., Luo N., Pobee J., Elliott AM., McAdam KP., Porter JD. 1998
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Pape JW., Jean SS., Ho JL., Hafner A., Johnson WD. 1993
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. Quigley MA., Mwinga A., Hosp M., Lisse I., Fuchs D., --, Godfrey-Faussett P. 2001
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. Whalen CC., Johnson JL., Okwera A., Hom DL., Huebner R., Mugyenyi P., Mugerwa RD., Ellner JJ. 1997
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Kaplan LD., Kahn JO., Crowe S., Northfelt D., Neville P., Grossberg H., Abrams DI., Tracey J., Mills J., Volberding PA. 1991
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Kaplan LD., Straus DJ., Testa MA., Von Roenn J., Dezube BJ., Cooley TP., Herndier B., Northfelt DW., Huang J., Tulpule A., Levine AM. 1997
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Mounier N., Spina M., Gabarre J., Raphael M., Rizzardini G., Golfier JB., Vaccher E., Carbone A., Coiffier B., Chichino G., Bosly A., Tirelli U., Gisselbrecht C. 2006
Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Bodsworth NJ., Bloch M., Bower M., Donnell D., Yocum R. 2001
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Northfelt DW., Dezube BJ., Thommes JA., Miller BJ., Fischl MA., Friedman-Kien A., Kaplan LD., Du Mond C., Mamelok RD., Henry DH. 1998
A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Stelzer KJ., Griffin TW. 1993
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. Stewart S., Jablonowski H., Goebel FD., Arasteh K., Spittle M., Rios A., Aboulafia D., Galleshaw J., Dezube BJ. 1998
Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. Walmsley S., Northfelt DW., Melosky B., Conant M., Friedman-Kien AE., Wagner B. 1999
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. Fischl M., Galpin JE., Levine JD., Groopman JE., Henry DH., Kennedy P., Miles S., Robbins W., Starrett B., Zalusky R. 1990
Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. Grossman HA., Goon B., Bowers P., Leitz G. 2003
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. Sulkowski MS., Dieterich DT., Bini EJ., Bräu N., Alvarez D., Dejesus E., Leitz GJ. 2005
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Bicanic T., Wood R., Meintjes G., Rebe K., Brouwer A., Loyse A., Bekker LG., Jaffar S., Harrison T. 2008
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Brouwer AE., Rajanuwong A., Chierakul W., Griffin GE., Larsen RA., White NJ., Harrison TS. 2004
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. Leenders AC., Reiss P., Portegies P., Clezy K., Hop WC., Hoy J., Borleffs JC., Allworth T., Kauffmann RH., Jones P., Kroon FP., Verbrugh HA., de Marie S. 1997
Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Mayanja-Kizza H., Oishi K., Mitarai S., Yamashita H., Nalongo K., Watanabe K., Izumi T., --, Augustine K., Mugerwa R., Nagatake T., Matsumoto K. 1998
A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Newton PN., Thai le H., Tip NQ., Short JM., Chierakul W., Rajanuwong A., Pitisuttithum P., Chasombat S., Phonrat B., Maek-A-Nantawat W., Teaunadi R., Lalloo DG., White NJ. 2002
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. van der Horst CM., Saag MS., Cloud GA., Hamill RJ., Graybill JR., Sobel JD., Johnson PC., Tuazon CU., Kerkering T., Moskovitz BL., Powderly WG., Dismukes WE. 1997
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. Kallestrup P., Zinyama R., Gomo E., Butterworth AE., Mudenge B., van Dam GJ., Gerstoft J., Erikstrup C., Ullum H. 2005
Effect of diethylcarbamazine on HIV load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tanzanians with or without lymphatic filariasis: randomized double-blind and placebo-controlled cross-over trial. Nielsen NO., Simonsen PE., Dalgaard P., Krarup H., Magnussen P., Magesa S., Friis H. 2007
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. Walson JL., Otieno PA., Mbuchi M., Richardson BA., Lohman-Payne B., Macharia SW., Overbaugh J., Berkley J., Sanders EJ., Chung MH., John-Stewart GC. 2008
Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. Fairfield WP., Finkelstein JS., Klibanski A., Grinspoon SK. 2001
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. Guaraldi G., Orlando G., Madeddu G., Vescini F., Ventura P., Campostrini S., Mura MS., Parise N., Caudarella R., Esposito R. -- Not Found --
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. Mondy K., Powderly WG., Claxton SA., Yarasheski KH., Royal M., Stoneman JS., Hoffmann ME., Tebas P. 2005
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. Negredo E., Martínez-López E., Paredes R., Rosales J., Pérez-Alvarez N., Holgado S., Gel S., del Rio L., Tena X., Rey-Joly C., Clotet B. 2005
A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Clifford DB., McArthur JC., Schifitto G., Kieburtz K., McDermott MP., Letendre S., Cohen BA., Marder K., Ellis RJ., Marra CM. 2002
A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. -- Not Found -- 1998
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Heseltine PN., Goodkin K., Atkinson JH., Vitiello B., Rochon J., Heaton RK., Eaton EM., Wilkie FL., Sobel E., Brown SJ., Feaster D., Schneider L., Goldschmidts WL., Stover ES. 1998
A phase I/II trial of nimodipine for HIV-related neurologic complications. Navia BA., Dafni U., Simpson D., Tucker T., Singer E., McArthur JC., Yiannoutsos C., Zaborski L., Lipton SA. 1998
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Sacktor N., Schifitto G., McDermott MP., Marder K., McArthur JC., Kieburtz K. 2000
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Schifitto G., Sacktor N., Marder K., McDermott MP., McArthur JC., Kieburtz K., Small S., Epstein LG. 1999
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Schifitto G., Zhang J., Evans SR., Sacktor N., Simpson D., Millar LL., Hung VL., Miller EN., Smith E., Ellis RJ., Valcour V., Singer E., Marra CM., Kolson D., Weihe J., Remmel R., Katzenstein D., Clifford DB. 2007

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: